Skip to main contentSkip to navigationSkip to search
HNSA (, %) SEK
Hansa Biopharma logotype

Hansa Medical has been granted European patent for diagnostic method HMD-301

Regulatory information
Hansa Medical AB, a biotechnology company focused on the development of innovative therapies and diagnostics for inflammatory disease, announced that the European Patent Office has granted a patent to cover the product candidate HMD-301.

The granted patent, EP 2129391 B1, covers any method that quantifies the level of Heparin Binding Protein, HBP, in a fluid sample from a patient and correlates this level with susceptibility to severe sepsis.

HMD-301 is Hansa Medical’s method for the quantification of HBP, which is under development in collaboration with British-Norwegian diagnostics company Axis-Shield Diagnostics Ltd., primarily to aid in the early identification and diagnosis of severe sepsis. A major multicenter clinical trial has been conducted in Sweden and USA, and the results are currently being evaluated.